Dr. Tamara L. Lenis, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 883
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
NJ license 25MA11422800 · NY license 303419 -
Retina Specialist (Ophthalmology) Physician
NJ license 25MA11422800 · NY license 303419
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Associated Retinal Consultants LLC (117 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 883
- Services billed
- 17,565
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 1,920 | 14 |
| Imaging of retina | 1,533 | 674 |
| Established patient complete exam of visual system | 1,511 | 647 |
| Injection, aflibercept, 1 mg | 1,366 | 177 |
| Extended exam of the back part of the eye with optic nerve drawing | 1,026 | 532 |
| Injection of drug into eye | 962 | 271 |
| Injection, ranibizumab, 0.1 mg | 950 | 58 |
| New patient office or other outpatient visit, 45-59 minutes | 290 | 290 |
| Photography of the retina | 283 | 232 |
| Extended exam of the back part of the eye with retinal drawing | 207 | 154 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Teaneck, NJ | 218 |
| Ketorolac Tromethamine Other prescribers in Teaneck, NJ | 100 |
| Latanoprost Other prescribers in Teaneck, NJ | 69 |
| Ofloxacin Other prescribers in Teaneck, NJ | 62 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Teaneck, NJ | 60 |
| Brimonidine Tartrate Other prescribers in Teaneck, NJ | 45 |
| Timolol Maleate Other prescribers in Teaneck, NJ | 19 |
| Dorzolamide Hcl Other prescribers in Teaneck, NJ | 18 |
| Atropine Sulfate | 14 |
| Restasis (cyclosporine) Other prescribers in Teaneck, NJ | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 26 payments worth $646 in total to this clinician.
| AbbVie Inc. | $191 |
|---|---|
| Bausch & Lomb Americas Inc. | $142 |
| Regeneron Healthcare Solutions, Inc. | $89.52 |
| Ani Pharmaceuticals, Inc. | $74.18 |
| Apellis Pharmaceuticals, Inc. | $59.84 |
| Neurotech Pharmaceuticals, Inc. | $36.50 |
| Harrow Eye, LLC | $35.65 |
| Astellas Pharma US Inc | $17.14 |
| Food and Beverage | $646 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $500 in research payments for these studies, mostly to the institutions running them.
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.